A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2
- Dexcom G7 is now connected with the t:slim X2 insulin pump by Tandem Diabetes Care in countries across Europe and in South Africa
- Dexcom is the most clinically studied CGM brand with AID capabilities
- New results from the COMISAIR seven-year follow up show significant and continued reduction of HbA1c and lower risk of diabetic retinopathy
- Dexcom G7 is the fastest CGM connected to the t:slim X2 insulin pump with a 30-minute sensor warmup time
- Dexcom offers industry-leading remote monitoring capabilities
- None.
The integration of Dexcom G7 Continuous Glucose Monitoring (CGM) System with the t:slim X2 insulin pump represents a significant advancement in diabetes care technology. This combination offers a more seamless and efficient management system for patients, potentially improving health outcomes. The COMISAIR study provides robust data, indicating a continued reduction of HbA1c levels and a lower risk of developing or progressing diabetic retinopathy when using the Dexcom CGM with the t:slim X2 pump. Such long-term studies are crucial for validating the effectiveness of medical technologies in real-world settings.
From a medical research perspective, the ability of an AID system to reduce HbA1c—a key indicator of long-term blood glucose control—is a strong indicator of its potential to reduce complications associated with Type 1 diabetes. The mention of significant health outcomes, such as the reduction of hypoglycemic events, aligns with the goals of diabetes management, which include maintaining blood glucose levels within a target range to prevent both acute and long-term complications.
The strategic partnership and technology integration between Dexcom and Tandem Diabetes Care could have a notable impact on the market dynamics within the diabetes care sector. Dexcom's established market leadership and extensive clinical research in CGM technology, combined with Tandem's innovative insulin pump, may enhance their competitive positioning. The expansion into European and South African markets indicates a strategic growth initiative, potentially increasing market share and revenue streams for both companies.
Moreover, the ability to remotely update existing devices is a testament to the companies' commitment to innovation and customer service. This capability may increase customer loyalty and reduce the need for physical replacements, ultimately leading to cost savings for both the company and the end-users. The integration's potential to improve patient outcomes could also lead to increased adoption rates, further boosting market performance.
In terms of health economics, the integration of Dexcom's CGM system with Tandem's insulin pump could lead to cost savings for healthcare systems over time. Improved glycemic control and reduced risk of complications such as diabetic retinopathy may translate to fewer hospitalizations and medical interventions, which are significant cost drivers in diabetes care. By potentially reducing the long-term healthcare costs associated with diabetes management, this technological advancement could be financially beneficial for both patients and healthcare providers.
Additionally, the ability to remotely update insulin pumps with new software could reduce the need for patients to purchase new devices as frequently, which can be a substantial financial burden. This approach not only aligns with the trends towards personalized and digital healthcare but also emphasizes the cost-effectiveness of maintaining and updating existing medical devices.
- With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most clinically studied‡‡ CGM brand with AID capabilities and the clear choice for powering AID systems1,2
- The clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are only proven when the system is connected to Dexcom CGM technology3
-
The power and accuracy of the Dexcom G7 is now combined with the discretion of the Tandem t:slim X2 insulin pump and will begin rolling out in countries across
Europe and inSouth Africa from today.
“For over a decade Dexcom has been pioneering industry leading CGM connectivity, meaning we have now safely powered AID systems for more than 1 million patient years of cumulative use. It’s therefore no wonder that Dexcom is the undisputed leader in CGM connectivity and why our sensors are the clear choice for AID systems,” said Jim Berkebile, Vice President Strategic Partners for EMEA at Dexcom. “Moreover, the clinically meaningful health outcomes that result from using the t:slim X2 insulin pump with Control-IQ technology are proven only when the system is connected to Dexcom CGM.”
Further solidifying Dexcom as the most studied CGM brand with AID capabilities, new results from the COMISAIR seven-year follow up – the longest prospective real-world CGM study ever conducted and presented by Dr. Jan Soupal at EASD 2023 – showed significant and continued reduction of HbA1c as well as a lower risk of the development or progression of diabetic retinopathy associated with the use of real-time CGM by people with Type 1 diabetes4. Additionally, the COMISAIR seven-year follow up demonstrated further substantial reduction in HbA1c when Dexcom CGM is connected to the t:slim X2 insulin pump with Control-IQ technology5.
“AID systems offer life-changing technology to people living with Type 1 diabetes,” said Dr. Emma Wilmot, Associate Professor, University of Nottingham. “Empowering those living with diabetes to manage their own condition and offering them the very best technology we can is vital for diabetes care. We know that when people combine real-time CGM and a pump to create an AID system they spend more time in range, experience fewer incidences of hypoglycaemia and enjoy greater peace of mind.”
Due to its 30 minute sensor warmup* the Dexcom G7 is the fastest CGM connected to the t:slim X2 insulin pump, meaning that those using a Dexcom G7 can spend more time benefiting from their AID system than with any other CGM. Dexcom G7 users can also share glucose data with loved ones and care teams in real time through industry-leading remote monitoring capabilities.‡
“As we celebrate our 10-year partnership with Dexcom, we remain committed to sustaining our rapid pace of innovation to further our mission of helping improve the lives of people with diabetes around the world,” said John Sheridan, President and Chief Executive Officer of Tandem Diabetes Care. “We’re actively engaged with our local distributors, supporting their efforts to make this exciting new integration available for new customers and to existing t:slim X2 pump users via remote software updates as quickly as possible.”
Tandem is working with local distributors in the countries listed below to support the launch of the t:slim X2 insulin pump with Dexcom G7 integration and the delivery of remote software updates for current eligible t:slim X2 users. Timing of new product shipments and pump software updates will vary by country and will take place throughout the first three months of 2024. Dexcom G7 integration with the t:slim X2 insulin pump will become available in the following countries:
To learn more and to get started with Dexcom G7 and the Tandem t:slim X2 insulin pump, visit Dexcom.co.uk/tandem.
The launch of Dexcom G7 and the Tandem t:slim X2 insulin pump further strengthens Dexcom’s position as the world’s most connected CGM.4 With more than 60 connected partners worldwide, Dexcom is committed to providing users with choice and flexibility when it comes to how they view their glucose data and deliver insulin.§
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in
‡‡ Dexcom CGM systems have been studied in over 50 registered interventional clinical trials (clinicaltrials.gov). Dexcom, Data on file 2023
*Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.
‡Separate Follow app and internet connection required.
§Reference www.dexcom.com/integrate.
1-2 Peacock S, et al. Diabetes Ther. 2023;14(5):839-855. 3 Dexcom, data on file, 2023. 4 Brown SA, et al. N Engl J Med. 2019;381(18):1707-1717. 5 Šoupal, J. Presented at EASD 2023,
View source version on businesswire.com: https://www.businesswire.com/news/home/20240115606690/en/
Media Contacts
James McIntosh
619-884-2118
james.mcintosh@dexcom.com
Gemma McDonald
+44 7826 900639
gemma.mcdonald@dexcom.com
Investor Contact
Sean Christensen
858-203-6657
sean.christensen@dexcom.com
Source: DexCom, Inc.
